Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
Main Authors: | Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
AVES
2021-07-01
|
Series: | European Journal of Rheumatology |
Online Access: | https://www.eurjrheumatol.org/en/long-term-safety-and-efficacy-of-olokizumab-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitor-therapy-in-phase-ii-studies-133413 |
Similar Items
-
Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
by: Taylor, P, et al.
Published: (2019) -
Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis
by: Dmitry S. Mikhaylenko, et al.
Published: (2022-04-01) -
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
by: Irina V. Bure, et al.
Published: (2020-10-01) -
The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01) -
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)